TY - JOUR
T1 - Evaluation of dosage-release formulations on inhibition of drug clearance
T2 - Effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters
AU - Bleske, Barry E.
AU - Welage, Lynda S.
AU - Touchette, Mark A.
AU - Edwards, David J.
AU - Rodman, Daniel P.
AU - Shea, Michael J.
PY - 1994/4
Y1 - 1994/4
N2 - Limited information exists regarding the influence of dosagerelease formulation on inhibition of drug metabolism. Therefore, the purpose of this study was to evaluate the effect of immediate-release (IR) and sustained-release (SR) verapamil on the pharmacokinetic parameters of propranolol in 12 healthy men. IR propranolol, 160 mg, was administered alone (Phase A) and following either IR verapamil, 80 mg t.i.d., (Phase B) or SR verapamil, 240 mg q.d., (Phase C) in a randomized crossover fashion. Of the 12 subjects enrolled, only seven were able to be analyzed secondary to assay interference. Oral clearances for L-propranolol for Phases A, B, and C were 198 ± 70, 156 ± 76, and 143 ± 85 L/h, respectively. Oral clearances for D-propranolol for Phases A, B, and C were 203 ± 96, 172 ± 96, and 152 ± 102 L/h, respectively. No significant differences were observed. However, when the verapamil groups (Phase B and C) were combined and compared to Phase A, a significant decrease in clearance for propranolol isomers was observed. In conclusion, due to the unexpected low numbers of patients evaluated, no significant differences in oral clearance were observed among the three treatment phases. However, there is a trend suggesting that SR verapamil had the greatest effect on propranolol clearance, which may warrant caution when changing from one formulation to another.
AB - Limited information exists regarding the influence of dosagerelease formulation on inhibition of drug metabolism. Therefore, the purpose of this study was to evaluate the effect of immediate-release (IR) and sustained-release (SR) verapamil on the pharmacokinetic parameters of propranolol in 12 healthy men. IR propranolol, 160 mg, was administered alone (Phase A) and following either IR verapamil, 80 mg t.i.d., (Phase B) or SR verapamil, 240 mg q.d., (Phase C) in a randomized crossover fashion. Of the 12 subjects enrolled, only seven were able to be analyzed secondary to assay interference. Oral clearances for L-propranolol for Phases A, B, and C were 198 ± 70, 156 ± 76, and 143 ± 85 L/h, respectively. Oral clearances for D-propranolol for Phases A, B, and C were 203 ± 96, 172 ± 96, and 152 ± 102 L/h, respectively. No significant differences were observed. However, when the verapamil groups (Phase B and C) were combined and compared to Phase A, a significant decrease in clearance for propranolol isomers was observed. In conclusion, due to the unexpected low numbers of patients evaluated, no significant differences in oral clearance were observed among the three treatment phases. However, there is a trend suggesting that SR verapamil had the greatest effect on propranolol clearance, which may warrant caution when changing from one formulation to another.
KW - Dosage-release formulation
KW - Drug metabolism
KW - Pharmacokinetics
KW - Propranolol
KW - Verapamil
UR - http://www.scopus.com/inward/record.url?scp=0028266289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028266289&partnerID=8YFLogxK
U2 - 10.1097/00007691-199404000-00019
DO - 10.1097/00007691-199404000-00019
M3 - Article
C2 - 8009573
AN - SCOPUS:0028266289
SN - 0163-4356
VL - 16
SP - 216
EP - 220
JO - Therapeutic drug monitoring
JF - Therapeutic drug monitoring
IS - 2
ER -